We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 29, 2021

Prophylaxis With Intrathecal or High-Dose Methotrexate Reduces the Risk of CNS Relapse in DLBCL

Blood Cancer Journal

 

Additional Info

Blood Cancer Journal
Prophylaxis With Intrathecal or High-Dose Methotrexate in Diffuse Large B-Cell Lymphoma and High Risk of CNS Relapse
Blood Cancer J 2021 Jun 16;[EPub Ahead of Print], S Bobillo, E Joffe, D Sermer, et al

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading